Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JFL Life SciencesNSE:JFLLIFE -1.43%67 PB Ratio is 0.91 as of Jul. 23, 2026, which is 41% below its 10-year median of 1.53. GuruFocus rates NSE:JFLLIFE with a GF Score™ of 67/100 and a GF Value™ of ₹36.05 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 921 Drug Manufacturers companies, JFL Life Sciences ranks better than 78.72% on this metric.
The historical rank and industry rank for JFL Life Sciences's PB Ratio or its related term are showing as below:
NSE:JFLLIFE'
s PB Ratio Range Over the Past 10 Years
Min: 0.75 Med: 1.53 Max: 6.16
Current: 0.91
During the past 7 years, JFL Life Sciences's highest PB Ratio was 6.16. The lowest was 0.75. And the median was 1.53.
NSE:JFLLIFE's PB Ratio is ranked better than 78.72% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs NSE:JFLLIFE: 0.91
During the past 12 months, JFL Life Sciences's average Book Value Per Share Growth Rate was 10.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 51.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 57.70% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of JFL Life Sciences was 81.70% per year. The lowest was 31.10% per year. And the median was 62.40% per year.
Back to Basics: PB Ratio
JFL Life Sciences (NSE:JFLLIFE) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
JFL Life Sciences PB Ratio Related Terms
JFL Life Sciences PB Ratio Historical Data
* Premium members only.
The historical data trend for JFL Life Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JFL Life Sciences PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where JFL Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
JFL Life Sciences (NSE:JFLLIFE) has a PB Ratio of 0.91 as of Jul. 23, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on JFL Life Sciences and its competitors. This is 41% below median its historical median of 1.53. Over the past decade, JFL Life Sciences' PB Ratio has ranged from 0.75 to 6.16. According to the industry distribution chart, JFL Life Sciences ranks #196 out of 921 companies in the Drug Manufacturers industry, placing it in the top 21.3%.
Is JFL Life Sciences' PB Ratio too high?
JFL Life Sciences' current PB Ratio of 0.91 is 41% below median its 10-year median of 1.53. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 6.16. The Drug Manufacturers industry median PB Ratio is 1.88. JFL Life Sciences' value of 0.91 is 51.6% below this industry median. Based on the distribution chart, JFL Life Sciences ranks #196 out of 921 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, JFL Life Sciences has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, JFL Life Sciences ranks #196 out of 921 companies for PB Ratio. This places JFL Life Sciences in the top 21% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.88. JFL Life Sciences' value of 0.91 is 51.6% below this benchmark. Historically, JFL Life Sciences' own PB Ratio has ranged from 0.75 to 6.16 over the past decade. While the company's 10-year median is 1.53 vs. the industry median of 1.88, JFL Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JFL Life Sciences's current PB Ratio of 0.91 is 51.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on JFL Life Sciences and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JFL Life Sciences's current PB Ratio is 0.91, which is 41% below median its own 10-year median of 1.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹36.05, compared to a current price of ₹10.35 — trading 71.3% below its estimated fair value. The current PB Ratio is 0.91, which is 41% below median its 10-year median of 1.53 and 51.6% below the Drug Manufacturers industry median of 1.88. JFL Life Sciences' overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current PB Ratio is 0.91 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued.
The current stock price of ₹10.35 is trading 71.3% below its estimated GF Value™ of ₹36.05.
GuruFocus considers JFL Life Sciences to be Significantly Undervalued.
Key valuation signals for NSE:JFLLIFE:
PB Ratio: 0.91 (41% below median its 10-year median of 1.53)
GF Value™: ₹36.05 vs. price of ₹10.35 (71.3% below fair value)
Industry Position: 51.6% below the Drug Manufacturers median (#196 of 921)
No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
67GF Score
Get the complete analysis for NSE:JFLLIFE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JFLLIFE has been successfully added to your 
